(Q35918439)

11 August 2017

1 reference

title

Therapy for recurrent malignant glioma in adults (English)

1 reference

11 August 2017

4

Patrick Y Wen

1 reference

11 August 2017

Maciej M Mrugala

1

1 reference

PubMed ID

15485312

11 August 2017

Santosh Kesari

series ordinal

2

1 reference

PubMed ID

15485312

11 August 2017

Naren Ramakrishna

series ordinal

3

1 reference

11 August 2017

1 October 2004

1 reference

Expert Review of Anticancer Therapy

11 August 2017

1 reference

11 August 2017

4

1 reference

11 August 2017

5

1 reference

11 August 2017

759-782

1 reference

Primary brain tumours in adults.

11 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

State-of-the-art treatment of high-grade brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Survival of human glioma cells treated with various combination of temozolomide and X-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

A comparison of treatment results for recurrent malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Recurrent malignant glioma in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Survival and functional status after resection of recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Role of radiation therapy and radiosurgery in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Selection bias, survival, and brachytherapy for glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Stereotactic radiosurgery for recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Targeted radiotherapy of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Temozolomide in combination with other cytotoxic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

PCV chemotherapy for recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Current chemotherapy for glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Pegylated liposomal doxorubicin-efficacy in patients with recurrent high-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Successful chemotherapy for recurrent malignant oligodendroglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Chemotherapy of anaplastic oligodendroglial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Signaling pathways regulating gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Genetic and signaling pathway alterations in glioblastoma relevance to novel targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Gene expression profiling identifies molecular subtypes of gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Perspectives on the development of a molecularly targeted agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Development of novel targeted therapies in the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Novel chemotherapeutic agents for the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Cannabinoids: potential anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

In vivo imaging of molecular-genetic targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Antiangiogenesis therapy. Current and future agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Angiogenesis in glioma: molecular mechanisms and roadblocks to translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Non-cytotoxic therapies for malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Human malignant glioma therapy using anti-alpha(v)beta3 integrin agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Clinical trials with retrovirus mediated gene therapy--what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Current and Future Gene Therapy for Malignant Gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Gene therapy for human malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a phase I trial in patients with recurrent malignant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Cytokine immuno-gene therapy for treatment of brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Reovirus as an oncolytic agent against experimental human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Clinical immunotherapy for brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Immunologic approaches to therapy for brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

Current management and prognostic factors for adult ependymoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.4.5.759

21 January 2018

Identifiers

DOI

10.1586/14737140.4.5.759

1 reference

11 August 2017

1 reference

PubMed ID

15485312